Grand Pharmaceutical Group Ltd
HKEX:512
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
PP&E Net
Grand Pharmaceutical Group Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
PP&E Net
HK$4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
PP&E Net
HK$5.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
PP&E Net
¥7.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
PP&E Net
¥9.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
PP&E Net
HK$24.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
PP&E Net
$94.8m
|
CAGR 3-Years
35%
|
CAGR 5-Years
31%
|
CAGR 10-Years
29%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's PP&E Net?
PP&E Net
4B
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's PP&E Net amounts to 4B HKD.
What is Grand Pharmaceutical Group Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
6%
Over the last year, the PP&E Net growth was 4%. The average annual PP&E Net growth rates for Grand Pharmaceutical Group Ltd have been 5% over the past three years , 4% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
